Disclosures for "The Effect of Antidopaminergic Medications on Changes in Clinical Measures of Huntington’s Disease Function, Cognition, Motor Signs, and Progression"
-
Dr. Hand has received personal compensation for serving as an employee of Prilenia Therapeutics.
-
Michal Geva has received personal compensation for serving as an employee of Prilenia Therapeutics. Michal Geva has received intellectual property interests from a discovery or technology relating to health care.
-
Paul Goldberg has received personal compensation for serving as an employee of Prilenia. Paul Goldberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ionis Pharmaceuticals. Paul Goldberg has stock in Prilenia.
-
Kelly Chen has received personal compensation for serving as an employee of Prilenia Therapeutics.
-
Jeffrey Long has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Triplet. Jeffrey Long has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vacinnex. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave. Jeffrey Long has received personal compensation in the range of $0-$499 for serving as a Consultant for PTC. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Jeffrey Long has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Jeffrey Long has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Jeffrey Long has received research support from NIH DSMB.
-
Michael Hayden has received personal compensation for serving as an employee of Prilenia Therapeutics. Michael Hayden has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CAMP4. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for AbCellera Biologics Inc.. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Ionis Pharmaceuticals . Michael Hayden has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for 89 Bio. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Oxford Biomedica . Michael Hayden has stock in Ionis Pharmaceuticals. Michael Hayden has stock in AbCellera Biologics Inc.. Michael Hayden has stock in 89 Bio. The institution of Michael Hayden has received research support from Canadian Institutes of Health Research. The institution of Michael Hayden has received research support from National Research Council Canada. The institution of Michael Hayden has received research support from Huntington Society of Canada. The institution of Michael Hayden has received research support from Bev Hartig Huntington Disease Foundation. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care.